TY - JOUR
T1 - Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals
AU - Otter, Ashley D.
AU - Jones, Scott
AU - Hicks, Bethany
AU - Bailey, Daniel
AU - Callaby, Helen
AU - Houlihan, Catherine
AU - Rampling, Tommy
AU - Gordon, Nicola Claire
AU - Selman, Hannah
AU - Satheshkumar, Panayampalli S.
AU - Townsend, Michael
AU - Mehta, Ravi
AU - Pond, Marcus
AU - Jones, Rachael
AU - Wright, Deborah
AU - Oeser, Clarissa
AU - Tonge, Simon
AU - Linley, Ezra
AU - Hemingway, Georgia
AU - Coleman, Tom
AU - Millward, Sebastian
AU - Lloyd, Aaron
AU - Damon, Inger
AU - Brooks, Tim
AU - Vipond, Richard
AU - Rowe, Cathy
AU - Hallis, Bassam
N1 - Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/12
Y1 - 2023/12
N2 - In early 2022, a cluster of monkeypox virus (MPXV) infection (mpox) cases were identified within the UK with no prior travel history to MPXV-endemic regions. Subsequently, case numbers exceeding 80,000 were reported worldwide, primarily affecting gay, bisexual, and other men who have sex with men (GBMSM). Public health agencies worldwide have offered the IMVANEX Smallpox vaccination to these individuals at high-risk to provide protection and limit the spread of MPXV. We have developed a comprehensive array of ELISAs to study poxvirus-induced antibodies, utilising 24 MPXV and 3 Vaccinia virus (VACV) recombinant antigens. Panels of serum samples from individuals with differing Smallpox-vaccine doses and those with prior MPXV infection were tested on these assays, where we observed that one dose of Smallpox vaccination induces a low number of antibodies to a limited number of MPXV antigens but increasing with further vaccination doses. MPXV infection induced similar antibody responses to diverse poxvirus antigens observed in Smallpox-vaccinated individuals. We identify MPXV A27 as a serological marker of MPXV-infection, whilst MPXV M1 (VACV L1) is likely IMVANEX-specific. Here, we demonstrate analogous humoral antigen recognition between both MPXV-infected or Smallpox-vaccinated individuals, with binding to diverse yet core set of poxvirus antigens, providing opportunities for future vaccine (e.g., mRNA) and therapeutic (e.g., mAbs) design.
AB - In early 2022, a cluster of monkeypox virus (MPXV) infection (mpox) cases were identified within the UK with no prior travel history to MPXV-endemic regions. Subsequently, case numbers exceeding 80,000 were reported worldwide, primarily affecting gay, bisexual, and other men who have sex with men (GBMSM). Public health agencies worldwide have offered the IMVANEX Smallpox vaccination to these individuals at high-risk to provide protection and limit the spread of MPXV. We have developed a comprehensive array of ELISAs to study poxvirus-induced antibodies, utilising 24 MPXV and 3 Vaccinia virus (VACV) recombinant antigens. Panels of serum samples from individuals with differing Smallpox-vaccine doses and those with prior MPXV infection were tested on these assays, where we observed that one dose of Smallpox vaccination induces a low number of antibodies to a limited number of MPXV antigens but increasing with further vaccination doses. MPXV infection induced similar antibody responses to diverse poxvirus antigens observed in Smallpox-vaccinated individuals. We identify MPXV A27 as a serological marker of MPXV-infection, whilst MPXV M1 (VACV L1) is likely IMVANEX-specific. Here, we demonstrate analogous humoral antigen recognition between both MPXV-infected or Smallpox-vaccinated individuals, with binding to diverse yet core set of poxvirus antigens, providing opportunities for future vaccine (e.g., mRNA) and therapeutic (e.g., mAbs) design.
UR - http://www.scopus.com/inward/record.url?scp=85172354267&partnerID=8YFLogxK
U2 - 10.1038/s41467-023-41587-x
DO - 10.1038/s41467-023-41587-x
M3 - Article
C2 - 37741831
AN - SCOPUS:85172354267
SN - 2041-1723
VL - 14
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5948
ER -
